The Ebola outbreak spreading across the Democratic Republic of the Congo and Uganda has a confirmed case-fatality rate of approximately 26 percent as of late June 2026 — meaning roughly one in four confirmed patients have died. With more than 1,100 total cases, this is now the third-largest Ebola outbreak ever documented globally, behind only the catastrophic 2014–2016 West Africa epidemic and the 2018–2020 DRC outbreak.
Understanding how this death rate compares to past Ebola outbreaks provides important context for assessing the outbreak's severity — both for the people directly affected in DRC and Uganda, and for American readers calibrating their level of concern as the CDC maintains active airport screening and a Level One emergency response.
Why This Matters
Not all Ebola outbreaks are equally lethal. The virus that causes Ebola disease belongs to a family of four species that cause illness in humans, each with a distinct historical case-fatality profile. Understanding which strain is responsible for a given outbreak — and that strain's historical lethality — is essential context that headline case counts alone do not provide.
According to the DRC's Ministry of Health and CDC confirmation, the current outbreak is caused by Bundibugyo virus (species Orthoebolavirus bundibugyoense) — a distinct species from the Zaire virus that caused the devastating 2014–2016 West Africa outbreak.
What We Know So Far
The ECDC's most recent epidemiological update, dated June 25, 2026, confirmed a total of 1,155 cases and 304 deaths in DRC, plus additional cases in Uganda — bringing the combined total past 1,100 with a case-fatality rate calculated at approximately 26 percent among confirmed cases.
This figure is consistent with the historical lethality of the Bundibugyo strain specifically. The Bundibugyo species was first identified in a 2007 outbreak in Uganda, where it caused death in approximately 30 percent of those infected — broadly similar to the rate observed in the current outbreak. A second Bundibugyo outbreak occurred in the DRC in 2012.
According to the CDC's historical Ebola data, the Bundibugyo species has historically been associated with somewhat lower case fatality rates than other Ebola species, though severe disease and death can still occur at substantial rates.
How This Compares to Other Major Ebola Outbreaks
2014–2016 West Africa Outbreak (Zaire virus): This remains the largest Ebola outbreak in recorded history, with more than 28,600 cases reported across Guinea, Liberia, and Sierra Leone, and more than 11,000 deaths — a case-fatality rate ranging from approximately 40 to 70 percent depending on the country and access to treatment. According to CDC historical data, without any treatment, Ebola virus disease caused by the Zaire strain can be fatal in up to 90 percent of cases — among the deadliest mortality rates of any infectious disease.
2018–2020 DRC Outbreak (Zaire virus): The second-largest outbreak in history, occurring in North Kivu province with a small number of cases crossing into Uganda, also caused by the Zaire strain. This outbreak benefited from the availability of an approved Ebola vaccine (Ervebo) and experimental therapeutics for the first time in a major outbreak, which contributed to improved survival outcomes compared to the 2014–2016 epidemic.
2007 Uganda Bundibugyo Outbreak: The first identified outbreak of this specific virus species, with a case-fatality rate of approximately 30 percent.
2012 DRC Bundibugyo Outbreak: A smaller outbreak with a case-fatality rate of approximately 55 percent, illustrating that even within the same viral species, fatality rates can vary significantly based on factors including health care access, patient age and underlying health, and how quickly cases are identified and isolated.
Current 2026 DRC/Uganda Outbreak (Bundibugyo virus): Approximately 26 percent case-fatality rate as of late June 2026, with more than 1,100 confirmed cases.
Why the Case-Fatality Rate Varies So Much
According to WHO guidance on Ebola disease, several factors influence case-fatality rates within and across outbreaks:
- Access to supportive care. Even without a specific antiviral treatment, aggressive supportive care — intravenous fluids, electrolyte correction, treatment of secondary infections, and management of bleeding complications — significantly improves survival.
- Speed of case identification and isolation. Earlier treatment initiation improves outcomes.
- Underlying health conditions. Malnutrition, concurrent infections (including malaria, which is endemic in the affected region), and other health vulnerabilities increase mortality risk.
- Conflict and access challenges. The current outbreak is occurring in an area affected by ongoing armed conflict from the Allied Democratic Force, which the WHO and CDC have both identified as limiting health care access for affected populations — a factor that could be elevating the case-fatality rate above what better access to care might achieve.
- Viral species and strain-specific virulence factors. Different Ebola species have intrinsically different virulence profiles based on their genetic characteristics.
The Treatment Gap That Distinguishes This Outbreak
A critical distinction between the current outbreak and the 2018–2020 DRC outbreak: no approved vaccine or treatment exists for Bundibugyo virus. Both approved Ebola vaccines — Ervebo and the Mvabea/Zabdeno regimen — target the Zaire strain specifically and provide no protection against Bundibugyo.
This means the current outbreak is being managed entirely through supportive care and infection control measures, without the additional mortality-reducing tools (vaccination of contacts, targeted therapeutics) that helped improve outcomes during the 2018–2020 DRC Zaire outbreak. WHO has convened expert panels to advise on candidate treatments and vaccines specifically for Bundibugyo virus, but none is currently approved or available at outbreak scale.
What Doctors and Experts Say
CDC modeling published in MMWR in June 2026 emphasized that the trajectory of case fatality depends heavily on how rapidly public health interventions — particularly case isolation — can be scaled. The same modeling work that projected outbreak size scenarios also implicitly affects fatality outcomes: more rapid isolation reduces both transmission and the risk that overwhelmed health systems will be unable to provide adequate supportive care to all patients.
What This Means for Americans
The CDC continues to assess the risk to the general American public as low, and no cases have been confirmed in the United States. The case-fatality comparison matters primarily for two reasons: it helps calibrate appropriate concern levels for the current outbreak relative to historical events, and it underscores why the absence of an approved vaccine or treatment for this specific strain makes early case identification and isolation — rather than medical countermeasures — the primary tool available to control it.
What You Can Do Now
- If you have recently traveled to DRC, Uganda, or South Sudan, monitor for Ebola symptoms for 21 days after departure and contact your state health department or 911 if symptoms develop — disclosing your travel history before arriving at a medical facility.
- Understand that the current outbreak's case-fatality rate, while serious, is lower than the historical rates seen in the 2014–2016 West Africa Zaire strain outbreak — useful context for calibrating personal risk assessment if you have connections to the affected region.
- Follow CDC.gov/ebola for ongoing updates on the outbreak's case-fatality trajectory and any developments regarding experimental treatments or vaccines for Bundibugyo virus.
What Happens Next
WHO-convened expert panels continue to evaluate candidate treatments and vaccines specifically for Bundibugyo virus. The case-fatality rate will continue to be monitored and may shift as the outbreak progresses, contact tracing improves, and health care access in conflict-affected areas evolves. MedicalDaily will report on any changes to the case-fatality trajectory and on developments in Bundibugyo-specific treatments or vaccines.
The Bottom Line
The current Ebola outbreak's 26 percent case-fatality rate, while serious and tragic for the more than 1,100 people affected, is notably lower than the 40 to 70 percent rates seen in the historic 2014–2016 West Africa Zaire strain outbreak. This reflects both the somewhat lower intrinsic virulence of the Bundibugyo species and the supportive care being provided despite significant challenges from ongoing armed conflict in the affected region. The absence of an approved vaccine or treatment for this strain, however, means containment continues to depend entirely on rapid case identification, isolation, and contact tracing — the same fundamental tools used to fight Ebola outbreaks since the virus was first identified in 1976.
